This week in drug discovery (8-12 April) 

News round-up for 8-12 April by DDW Digital Content Editor Diana Spencer.

The cancer research news has been coming thick and fast from the American Association of Cancer Research (AACR) Annual Meeting in San Diego this week, so our Friday round-up focuses on drug discovery in oncology.

The top stories:

Genetically engineered dendritic cells enhance lung cancer therapy

A study by researchers at the UCLA Health Jonsson Comprehensive Cancer Center in the US suggests that injecting engineered dendritic cells directly into cancerous lung tumours can help promote a stronger immune response.

News from AACR 2024: Monday’s highlights

Dr Zev Wainberg, Co-Director of the UCLA Health GI Oncology Program, presented results from pilot study, which suggests that for people with borderline resectable pancreatic cancer, administrating an immunotherapy drug in combination with chemotherapy before surgery is safe and may improve long-term outcomes.

GSK’s endometrial cancer therapy approved in Scotland

The Scottish Medicines Consortium (SMC) has accepted GSK’s dostarlimab as a treatment for adult patients with endometrial cancer when used in combination with platinum-containing chemotherapy.

Study casts doubt on benefit of ‘accelerated approval’ cancer drugs

Forty-one percent of cancer drugs granted accelerated approval from 2013 to 2017 did not demonstrate clinical benefit in confirmatory trials, according to a study in the Journal of the American Medical Association (JAMA).

First tumour agnostic HER2 directed ADC gets US approval

Daiichi Sankyo and AstraZeneca’s Enhertu (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumours.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free